A systematic review and economic model of the effectiveness and ...

TABLE 14 ER-MPH medium dose (20–40 mg/day) versus placebo
Study Design Intervention – N Age Duration Core outcomes
(years) (weeks)
Administered once daily
Wolraich, 2001 97 P OROS MPH (Concerta) (18, 36 or 6–12 4 Core: SNAP-IV: hyperactivity/impulsivity (parent, teacher)
54 mg/day, o.d.) – 312 QoL: CGI improvement (investigators)
AE: solicited and spontaneous reports: focus on sleep
quality, tics and appetite (parent)
Greenhill, 2002 59 P MPH-Modified Release (Metadate CD) 5–15 3 Core: not reported
(mean 40.7 mg/day, o.d.) – 321 QoL: CGI (teacher; parent); CGI improvement ratings
AE: Teacher and Parent Side-Effect Questionnaires
Quinn, 2003 84 [Confidential information removed]
Dopfner, 200348 P MPH-Retard (Medikinet) (20–60 mg/day, 6–16 4 Core: no hyp; Peer Assessment for Hyperkinetic Disorders
o.d.) – 85 (teachers); effectiveness scale (parents, physicians)
QoL: not reported
AE: no specific scale reported
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Stein, 2003 92 C (4×) OROS MPH (Concerta) (36 mg/day, 5.9–16 4 Core: no hyp; ADHD Rating Scale IV (parents)/ACTeRS
o.d.) – 47 QoL: CGI
AE: SERS (parents)
Swanson, 2004 32 C (3×) OROS MPH (Concerta) (18, 36 or 6–12 3 Core: no hyp; SKAMP: deportment; attention (measured by
54 mg/day, o.d.) – 184 two trained observers)
QoL: not reported
MPH-Modified Release (Metadate CD) AE: side-effects on the Barkley Scale
(20, 40 or 60 mg/day, o.d.) –184
Health Technology Assessment 2006; Vol. 10: No. 23
C, crossover trial (number of crossovers); CGI, Clinical Global Improvement; P, parallel trial; SKAMP, Swanson, Kotkin Agler, M-Flynn, Pelham (scale); SNAP, Swanson, Nolan and
Pelham (scale).
39